MedTrace Logo

Intravenous and Perineural Dexamethasone for Ultrasound-Guided Axillary Blocks

NCT02629835 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-03-22

No results posted yet for this study

Summary

Dexamethasone prolong the duration of brachial plexus blocks, but the optimal route, intravenous (IV) or perineural (PN), remains controversial.

This Multi-centric trial compare IV and PN dexamethasone for ultrasound-guided axillary brachial plexus blocks (AXBs). Research hypothesis is that PN modality will outlast its IV counterpart. Since analgesic duration and sensory duration can be influenced by intake of pain medications and surgical trauma to small cutaneous nerves, the investigators will select motor block duration as the main outcome.

Conditions

  • Brachial Plexus Block Duration

Interventions

OTHER

intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution

OTHER

intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone

Sponsors & Collaborators

  • Montreal General Hospital

    lead OTHER

Principal Investigators

  • De QH Tran, MD, FRCPC · Associate Professor

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Canada
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02629835 on ClinicalTrials.gov